Silvan Tuerkcan
Stock Analyst at Citizens
(4.32)
# 365
Out of 5,147 analysts
176
Total ratings
48.28%
Success rate
19.36%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $60.14 | +43.00% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $42.12 | +35.33% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $5.91 | +69.20% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $10.11 | +107.72% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.78 | +52.39% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.53 | +76.60% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $10.90 | +101.83% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.38 | +334.78% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $12.33 | +175.75% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $32.20 | +39.75% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $44.06 | +13.48% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $6.21 | +141.55% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $4.62 | +29.87% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.68 | +58.45% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $15.44 | +677.20% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.51 | +1,025.83% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.25 | +77.78% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $10.26 | +104.68% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.99 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.88 | +54.64% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $72.64 | +285.46% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.33 | +74.25% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $60.14
Upside: +43.00%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $42.12
Upside: +35.33%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $5.91
Upside: +69.20%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $10.11
Upside: +107.72%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.78
Upside: +52.39%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.53
Upside: +76.60%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $10.90
Upside: +101.83%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.38
Upside: +334.78%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $12.33
Upside: +175.75%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $32.20
Upside: +39.75%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.06
Upside: +13.48%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.21
Upside: +141.55%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.62
Upside: +29.87%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.68
Upside: +58.45%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $15.44
Upside: +677.20%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.51
Upside: +1,025.83%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.25
Upside: +77.78%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $10.26
Upside: +104.68%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.99
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.88
Upside: +54.64%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $72.64
Upside: +285.46%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.33
Upside: +74.25%